

# Charalampos Pontikoglou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11694810/publications.pdf>

Version: 2024-02-01

36  
papers

1,190  
citations

430843

18  
h-index

377849

34  
g-index

36  
all docs

36  
docs citations

36  
times ranked

2285  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mesenchymal Stem Cells Derived from Wharton's Jelly of the Umbilical Cord: Biological Properties and Emerging Clinical Applications. <i>Current Stem Cell Research and Therapy</i> , 2013, 8, 144-155.	1.3	192
2	Bone Marrow Mesenchymal Stem Cells: Biological Properties and Their Role in Hematopoiesis and Hematopoietic Stem Cell Transplantation. <i>Stem Cell Reviews and Reports</i> , 2011, 7, 569-589.	5.6	160
3	Specific Lineage-Priming of Bone Marrow Mesenchymal Stem Cells Provides the Molecular Framework for Their Plasticity. <i>Stem Cells</i> , 2009, 27, 1142-1151.	3.2	110
4	Reserves, Functional, Immunoregulatory, and Cytogenetic Properties of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes. <i>Stem Cells and Development</i> , 2010, 19, 1043-1054.	2.1	63
5	Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells. <i>Stem Cell Research and Therapy</i> , 2017, 8, 102.	5.5	62
6	Chitosan/gelatin scaffolds support bone regeneration. <i>Journal of Materials Science: Materials in Medicine</i> , 2018, 29, 59.	3.6	56
7	Bone regeneration: the stem/progenitor cells point of view. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 103-115.	3.6	50
8	Adhesion and growth of human bone marrow mesenchymal stem cells on precise-geometry 3D organic-inorganic composite scaffolds for bone repair. <i>Materials Science and Engineering C</i> , 2015, 48, 301-309.	7.3	45
9	Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. <i>HemaSphere</i> , 2019, 3, e168.	2.7	41
10	Human bone marrow native mesenchymal stem cells. <i>Regenerative Medicine</i> , 2008, 3, 731-741.	1.7	39
11	CD200 expression in human cultured bone marrow mesenchymal stem cells is induced by pro-osteogenic and pro-inflammatory cues. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 655-665.	3.6	37
12	CD200R/CD200 Inhibits Osteoclastogenesis: New Mechanism of Osteoclast Control by Mesenchymal Stem Cells in Human. <i>PLoS ONE</i> , 2013, 8, e72831.	2.5	33
13	Recombinant human bone morphogenetic protein 2 (rhBMP-2) immobilized on laser-fabricated 3D scaffolds enhance osteogenesis. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 149, 233-242.	5.0	32
14	Study of the Quantitative, Functional, Cytogenetic, and Immunoregulatory Properties of Bone Marrow Mesenchymal Stem Cells in Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Stem Cells and Development</i> , 2013, 22, 1329-1341.	2.1	27
15	Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. <i>Expert Review of Hematology</i> , 2008, 1, 217-229.	2.2	26
16	Mesenchymal Stem Cells in Immune-Mediated Bone Marrow Failure Syndromes. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-10.	3.3	22
17	Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes. <i>Current Stem Cell Research and Therapy</i> , 2011, 6, 122-130.	1.3	20
18	Mesenchymal Stem Cells Contribute to the Abnormal Bone Marrow Microenvironment in Patients with Chronic Idiopathic Neutropenia by Overproduction of Transforming Growth Factor- $\beta$ 1. <i>Stem Cells and Development</i> , 2011, 20, 1309-1318.	2.1	19

#	ARTICLE	IF	CITATIONS
19	Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2011, 4, 317-328.	2.2	18
20	High Frequency of Thyroid Disorders in Patients Presenting With Neutropenia to an Outpatient Hematology Clinic STROBE-Compliant Article. <i>Medicine (United States)</i> , 2015, 94, e886.	1.0	17
21	Circulating Endothelial Progenitor Cells in Hypertensive Patients With Increased Arterial Stiffness. <i>Journal of Clinical Hypertension</i> , 2014, 16, 295-300.	2.0	16
22	Evidence for downregulation of erythropoietin receptor in bone marrow erythroid cells of patients with chronic idiopathic neutropenia. <i>Experimental Hematology</i> , 2006, 34, 1312-1322.	0.4	15
23	Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. <i>Blood</i> , 2021, 138, 1249-1257.	1.4	15
24	Wharton&#39;s Jelly Mesenchymal Stem Cell Response on Chitosan-graft-poly (&#949;-caprolactone) Copolymer for Myocardium Tissue Engineering. <i>Current Pharmaceutical Design</i> , 2014, 20, 2030-2039.	1.9	13
25	Increased Mobilization of Mesenchymal Stem Cells in Patients With Essential Hypertension: The Effect of Left Ventricular Hypertrophy. <i>Journal of Clinical Hypertension</i> , 2014, 16, 883-888.	2.0	10
26	Osteogenic differentiation of bone marrow mesenchymal stem cells on chitosan/gelatin scaffolds: gene expression profile and mechanical analysis. <i>Biomedical Materials (Bristol)</i> , 2020, 15, 064101.	3.3	10
27	The âˆ’509C/T polymorphism of transforming growth factorâ€™21 is associated with increased risk for development of chronic idiopathic neutropenia. <i>European Journal of Haematology</i> , 2009, 83, 535-540.	2.2	8
28	Using Electronic Patient Reported Outcomes to Foster Palliative Cancer Care: The MyPal Approach. , 2019, , .		8
29	Endothelial progenitor cells as markers of severity in hypertrophic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2016, 18, 179-184.	7.1	6
30	Increased levels of soluble flt-3 ligand in serum and long-term bone marrow culture supernatants in patients with chronic idiopathic neutropenia. <i>British Journal of Haematology</i> , 2006, 132, 637-639.	2.5	5
31	Increased proportion and altered properties of intermediate monocytes in the peripheral blood of patients with lower risk Myelodysplastic Syndrome. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 86, 102507.	1.4	4
32	Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2021, 138, 1535-1535.	1.4	3
33	Soluble c-kit ligand production by bone marrow stromal cells is independent of the degree of neutropenia in patients with chronic idiopathic neutropenia. <i>Annals of Hematology</i> , 2006, 85, 170-173.	1.8	2
34	Lymphopenia in patients with chronic idiopathic neutropenia is associated with decreased number of Tâ€™lymphocytes containing Tâ€™cell receptor excision circles. <i>European Journal of Haematology</i> , 2012, 88, 210-223.	2.2	2
35	Immunoglobulin and B-cell disturbances in patients with chronic idiopathic neutropenia. <i>Clinical Immunology</i> , 2017, 183, 75-81.	3.2	2
36	Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 538-540.	1.3	2